Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 2/20 | 0.64 |
| ▸ | CTSS | P25774 | 1/20 | 0.64 |
| ▸ | CTSK | P43235 | 1/20 | 0.64 |
| ▸ | ACE | P12821 | 4/20 | 0.61 |
| ▸ | MAPT | P10636 | 2/20 | 0.59 |
| ▸ | TP53 | P04637 | 1/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.57 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.56 |
| ▸ | CCKBR | P32239 | 4/20 | 0.55 |
| ▸ | TACR1 | P25103 | 2/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | REN | P00797 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23677892 | 1.00 | CTSL (0.64) | CTSLCTSSCTSKACEMAPT | |
| SCHEMBL24445577 | 1.00 | CTSL (0.64) | CTSLCTSSCTSKACEMAPT | |
| SCHEMBL18395822 | 1.00 | CTSL (0.64) | CTSLCTSSCTSKACEMAPT | |
| SCHEMBL23587982 | 0.91 | IDO1 (0.56) | CTSLCTSSCTSKACEMAPT | |
| SCHEMBL23677933 | 0.91 | IDO1 (0.56) | CTSLCTSSCTSKACEMAPT | |
| SCHEMBL18396013 | 0.91 | IDO1 (0.56) | CTSLCTSSCTSKACEMAPT | |
| SCHEMBL18395829 | 0.91 | TACR1 (0.61) | CTSLCTSSCTSKACEMAPT | |
| SCHEMBL18396335 | 0.91 | TACR1 (0.61) | CTSLCTSSCTSKACEMAPT | |
| SCHEMBL23677934 | 0.91 | TACR1 (0.61) | CTSLCTSSCTSKACEMAPT | |
| SCHEMBL27871524 | 0.90 | CTSL (0.76) | CTSLCTSSCTSKACEMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3613420-B1 | SALTS AND PRODRUGS OF 1-METHYL-D-TRYPTOPHAN | LUMOS PHARMA INC (US) | 2022-05-25 | — | — | EP | disclosed |
| EP-3324958-B1 | SALTS AND PRODRUGS OF 1-METHYL-D-TRYPTOPHAN | LUMOS PHARMA INC (US) | 2021-07-28 | — | — | EP | disclosed |
| US-20200283385-A1 | SALTS AND PRODRUGS OF 1-METHYL-D-TRYPTOPHAN | LUMOS PHARMA, INC. | 2020-09-10 | — | — | US | disclosed |
| US-20200283385-A1 | SALTS AND PRODRUGS OF 1-METHYL-D-TRYPTOPHAN | LUMOS PHARMA, INC. | 2020-09-10 | — | — | US | disclosed |
| EP-3613420-A1 | SALTS AND PRODRUGS OF 1-METHYL-D-TRYPTOPHAN | Newlink Genetics Corporation (US) | 2020-02-26 | — | — | EP | disclosed |
| US-20190248739-A1 | SALTS AND PRODRUGS OF 1-METHYL-D-TRYPTOPHAN | LUMOS PHARMA, INC. | 2019-08-15 | — | — | US | disclosed |
| US-20190248739-A1 | SALTS AND PRODRUGS OF 1-METHYL-D-TRYPTOPHAN | LUMOS PHARMA, INC. | 2019-08-15 | — | — | US | disclosed |
| US-10207990-B2 | Salts and prodrugs of 1-methyl-D-tryptophan | NEWLINK GENETICS CORPORATION (US) | 2019-02-19 | — | — | US | disclosed |
| US-10207990-B2 | Salts and prodrugs of 1-methyl-D-tryptophan | NEWLINK GENETICS CORPORATION (US) | 2019-02-19 | — | — | US | disclosed |
| US-20180134658-A1 | SALTS AND PRODRUGS OF 1-METHYL-D-TRYPTOPHAN | LUMOS PHARMA, INC. | 2018-05-17 | — | — | US | disclosed |
| US-20180134658-A1 | SALTS AND PRODRUGS OF 1-METHYL-D-TRYPTOPHAN | LUMOS PHARMA, INC. | 2018-05-17 | — | — | US | disclosed |
| US-9732035-B2 | Salts and prodrugs of 1-methyl-D-tryptophan | NEWLINK GENETICS CORPORATION (US) | 2017-08-15 | — | — | US | disclosed |
| US-9732035-B2 | Salts and prodrugs of 1-methyl-D-tryptophan | NEWLINK GENETICS CORPORATION (US) | 2017-08-15 | — | — | US | disclosed |
| US-20170022157-A1 | SALTS AND PRODRUGS OF 1-METHYL-D-TRYPTOPHAN | LUMOS PHARMA, INC. | 2017-01-26 | — | — | US | disclosed |
| US-20170022157-A1 | SALTS AND PRODRUGS OF 1-METHYL-D-TRYPTOPHAN | LUMOS PHARMA, INC. | 2017-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190248739-A1 | SALTS AND PRODRUGS OF 1-METHYL-D-TRYPTOPHAN | IDO1, IDO2, INMT | CTSL 2973/4885CTSS 3725/4885CTSK 4158/4885 |
| US-10207990-B2 | Salts and prodrugs of 1-methyl-D-tryptophan | IDO1, IDO2, INMT | CTSL 2973/4885CTSS 3725/4885CTSK 4158/4885 |
| US-20200283385-A1 | SALTS AND PRODRUGS OF 1-METHYL-D-TRYPTOPHAN | IDO1, IDO2, INMT | CTSL 2973/4885CTSS 3725/4885CTSK 4158/4885 |
| US-20170022157-A1 | SALTS AND PRODRUGS OF 1-METHYL-D-TRYPTOPHAN | IDO1, IDO2, INMT | CTSL 2973/4885CTSS 3725/4885CTSK 4158/4885 |
| US-20180134658-A1 | SALTS AND PRODRUGS OF 1-METHYL-D-TRYPTOPHAN | IDO1, IDO2, INMT | CTSL 2973/4885CTSS 3725/4885CTSK 4158/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.